

Lantz Keri
Form 3
January 07, 2019

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Lantz Keri

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

01/01/2019

3. Issuer Name **and** Ticker or Trading Symbol

ACHILLION PHARMACEUTICALS INC [ACHN]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

___ Director ___ 10% Owner

☒ Officer ___ Other
(give title below) (specify below)

See Remarks

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting
Person

___ Form filed by More than One
Reporting Person

C/O ACHILLION
PHARMACEUTICALS,
INC.,Â 300 GEORGE STREET

(Street)

NEW HAVEN,Â CTÂ 06511

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

11,848

D

Â

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

4. Conversion
or Exercise
Price of
Derivative

5. Ownership
Form of
Derivative
Security:

6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: Lantz Keri - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option	Â <u>(1)</u>	12/18/2019	Common Stock	13,000	\$ 3.28	D	Â
Employee Stock Option	Â <u>(1)</u>	12/16/2020	Common Stock	25,000	\$ 3.1	D	Â
Employee Stock Option	Â <u>(1)</u>	12/12/2021	Common Stock	9,500	\$ 7.59	D	Â
Employee Stock Option	Â <u>(1)</u>	12/18/2022	Common Stock	12,900	\$ 8.64	D	Â
Employee Stock Option	Â <u>(1)</u>	12/17/2023	Common Stock	20,000	\$ 3.02	D	Â
Employee Stock Option	Â <u>(1)</u>	12/04/2024	Common Stock	14,100	\$ 13.8	D	Â
Employee Stock Option	Â <u>(2)</u>	01/25/2026	Common Stock	18,000	\$ 7.54	D	Â
Employee Stock Option	Â <u>(3)</u>	07/25/2026	Common Stock	6,000	\$ 8.42	D	Â
Employee Stock Option	Â <u>(4)</u>	01/25/2027	Common Stock	30,000	\$ 4.17	D	Â
Employee Stock Option	Â <u>(5)</u>	02/16/2028	Common Stock	75,000	\$ 3.2	D	Â
Employee Stock Option	Â <u>(6)</u>	08/06/2028	Common Stock	10,000	\$ 2.52	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lantz Keri C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN, CT 06511	Â	Â	Â See Remarks	Â

Signatures

/s/ Keri Lantz 01/07/2019

____Signature of Date
Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option is fully vested and exercisable.

(2) This option was granted on January 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

(3) This option was granted on July 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

(4) This option was granted on January 25, 2017 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

(5) This option was granted on February 16, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

(6) This option was granted on August 6, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

Â

Remarks:

ViceÂ PresidentÂ ofÂ Finance,Â CorporateÂ Controller,Â InterimÂ PrincipalÂ FinancialÂ OfficerÂ andÂ InterimÂ Principa

SeeÂ ExhibitÂ 24.1,Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.